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Abstract
Background and objectives
High monocyte counts are related to adverse outcomes in cardiovascular disease. Their
role in prognostication in patients with atrial fibrillation (AF) is unknown. We investigated
whether monocyte counts are useful as a marker of prognosis in patients with AF.
Methods
Monocyte counts were obtained from blood samples in 881 AF patients. Study outcomes
were (i) all-cause death; (ii) major adverse cardiovascular events; (iii) stroke, TIA or other
systemic embolism (SSE); and (iv) major bleeding.
Results
Median follow up was 7.2 years; 44% of patients died, 48% developed MACE; 9% had
SSE and 5% had major bleeding. On Cox regression, after adjustment for CHA2DS2-VASc
score, the highest quartile of monocyte counts (i.e.,580 μL vs. other quartiles) was associ-
ated with increased risk of death (hazard ratio [HR] 1.64, 95% confidence interval [CI] 1.31–
2.05, p<0.001) and MACE (HR 1.58, 95% CI 1.28–1.96, p<0.001). Persistent monocyte lev-
els580 per μL during follow up were associated with further increase in risk of death (HR
1.52, 95% CI 1.10–2.11, p = 0.01) and MACE (HR 1.54, 95% CI 1.13–2.09, p = 0.006). Per-
sistent monocyte levels580 per μL during were associated with a significant increase in
major bleeding events (HR 2.77, 95% CI 1.36–5.67, p = 0.005, after adjustment for HAS-
BLED score).
Conclusion
High monocyte counts independently predict the occurrence of MACE, major bleeding and
mortality, but not SSE. Understanding the pathophysiological mechanisms involved would
help understand the relationships between monocytes, and adverse thrombotic and bleed-
ing outcomes in AF patients.
PLOS ONE | https://doi.org/10.1371/journal.pone.0200373 July 18, 2018 1 / 12
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Shahid F, Rahmat NA, Lip GYH, Shantsila
E (2018) Prognostic implication of monocytes in
atrial fibrillation: The West Birmingham Atrial
Fibrillation Project. PLoS ONE 13(7): e0200373.
https://doi.org/10.1371/journal.pone.0200373
Editor: Yoshiaki Taniyama, Osaka University
Graduate School of Medicine, JAPAN
Received: January 18, 2018
Accepted: June 20, 2018
Published: July 18, 2018
Copyright: © 2018 Shahid et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: The study was
approved by the Black Country Research and
Ethics Committee, West Midlands, UK. Availability
of data and materials is limited due to legal
restrictions pertaining to use of patient data,
deidentified data are available upon request from
Ronnie Haynes ronnie.haynes@nhs.net, provided
relevant ethical and legal permissions have been
attained priorly, and researchers meet the criteria
for access to confidential data.
Funding: The authors received no specific funding
for this work.
Introduction
Circulating monocytes have been closely linked to outcomes in patients with cardiovascular
disease[1]. The primary role of monocytes is to detect and replenish the stores of macrophages
and dendritic cells, and to provide phagocytosis of pathogens[2]. Monocytes make up to 8% of
the peripheral blood white cells and play a central role in the host response to infective agents,
such as bacteria and viruses. Additionally, monocytes modulate the inflammatory processes,
producing both pro- and anti-inflammatory cytokines and developing macrophages with pro-
and anti-inflammatory phenotype[3].
Research into the role of inflammation in cardiovascular disease has found increased
monocyte counts in patients with a myocardial infarction and other forms of acute cardiovas-
cular pathology[1, 4, 5]. Monocyte-derived “foam cell” macrophages are a substrate for athero-
sclerosis and thus facilitate the progress to myocardial infarction. Overall, monocytes have
been used as indicators of prognosis in humans with their high numbers being associated with
increased risk of recurrent myocardial infarction, hospitalization and cardiac death[1]. Avail-
able data indicate that monocyte mobilization in acute cardiac disease does not simply reflect a
response to cardiac damage, as they are actively involved in the pathological processes them-
selves [6, 7].
Introduction of oral anticoagulation has dramatically reduced the risk of stroke. However,
the contemporary outcomes in Atrial Fibrillation (AF) are increasingly driven by non-embolic
events and complication of oral anticoagulation (bleeding). The role of monocytes in deter-
mining outcomes amongst AF patients is unknown. Such data could help identify patients at
high risk of adverse outcomes and subsequently highlight those in need of targeted therapy to
control cardiovascular risk factors as well as novel therapeutic strategies aimed at modulating
the inflammatory response in AF patients.
Our aim was to investigate the prognostic roles of monocyte counts in AF for the occur-
rence of death, major adverse cardiovascular events (MACE), stroke and systemic embolism
(SSE), as well as significant bleeding events in a longer term observational study cohort of AF
patients. We tested the hypothesis that high monocyte counts confer an increased risk of these
adverse outcome.
Methods
Patients with documented AF were recruited from outpatient Atrial fibrillation clinics in
Sandwell and West Birmingham Hospitals Trust and Oral anticoagulation clinics in the West
Birmingham area between August 2008 and August 2010 (Table 1). There has been no patient
selection based on co-morbidities. All recruited patients were included into the analysis if they
had data on monocyte counts after the diagnosis of AF (36 [4%] of the patients were excluded
for this reason). A total of 881 patients with data on monocyte counts were included in this
analysis. Data on blood monocyte counts during routine appointments after a diagnosis of AF
were obtained from clinical records. Monocyte data from acute admissions were not included.
Follow up monocyte data were collected from routine appointments at one-year time or near-
est later date and were available for 670 patients.
Patients were prospectively followed up with clinical outcomes recorded based on clinical
records. The study outcomes were (i) any-cause death; (ii) major adverse cardiovascular events
(MACE: first event of death, myocardial infarction, ischemic stroke, transient ischemic attacks
(TIA) or other systemic embolism); (iii) stroke, TIA or other systemic embolism (SSE); and
(iv) major bleeding (including hemorrhagic stroke). The study was approved by the Black
Country Research and Ethics Committee, UK and the study complied with the Declaration
of Helsinki. All patients provided written informed consent for participation in the study.
Monocytes in atrial fibrillation
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Table 1. Clinical characteristics and study outcomes of patients at baseline and follow up.
All (n = 881) OAC (n = 524) No OAC (n = 357)
Age (years) 71 (62–78) 72 (64–79) 68 (58–78)
Male sex (n) 524 (59%) 308 (59%) 216 (61%)
Non-White ethnicity (n) 171 (20%) 82 (16%) 89 (25%)
CHA2DS2-VASc score 3.3±1.5 3.5±1.4 3.0±1.6
HAS-BLED score 1.4±0.8 1.2±0.7 1.7±0.9
Monocytes (per μL) 0.45 (0.36–0.58) 0.36 (0.46–0.58) 0.36 (0.45–0.58)
Monocyte count >800 per μL (n) 69 (7.8%) 34 (6.5%) 35 (9.8%)
Body mass index (kg/m2) 28 (25–33) 25 (29–34) 25 (28–32)
Systolic BP (mm Hg) 137 (123–152) 122 (137–151) 124 (138–153)
Diastolic BP (mm Hg) 80 (72–90) 72 (80–90) 71 (80–90)
Creatinine (μmol/L) 90 (76–106) 91 (78–107) 90 (74–105)
Atrial fibrillation type
Paroxysmal 337 (38%) 137 (26%) 200 (56%)
Persistent 116 (13%) 84 (16%) 32 (9%)
Long standing persistent or permanent 428 (49%) 303 (58%) 125 (35%)
Past medical history
Myocardial infarction (n) 129 (14%) 72 (13%) 57 (15%)
Congestive heart failure (n) 153 (17%) 112 (21%) 41 (11%)
Coronary artery bypass grafting (n) 30 (3%) 19 (4%) 11 (3%)
Percutaneous coronary (n) 30 (3%) 14 (3%) 16 (4%)
Peripheral artery disease (n) 26 (4%) 15 (3%) 11 (4%)
End-stage renal failure (n) 5 (1%) 1 (0.2%) 4 (1%)
End-stage liver failure (n) 3 (0.3%) 1 (0.2%) 2 (1%)
Alcohol excess (n) 32 (4%) 12 (2%) 20 (6%)
Pharmacotherapy
Beta-blocker (n) 396 (45%) 234 (45%) 162 (45%)
Amiodarone or flecainide (n) 95 (11%) 47 (9%) 48 (13%)
Angiotensin receptor blocker (n) 212 (24%) 126 (24%) 86 (24%)
ACE inhibitors (n) 320 (36%) 209 (40%) 111 (31%)
Anti-anginal agents (n) 73 (8%) 38 (7%) 35 (10%)
Statin (n) 342 (39%) 200 (38%) 142 (40%)
Digoxin (n) 238 (27%) 181 (35%) 57 (16%)
Dihydropyridine CCA (n) 191 (22%) 107 (20%) 84 (24%)
Non-dihydropyridine CCA (n) 203 (23%) 127 (24%) 76 (21%)
Diuretics 393 (45%) 268 (51%) 125 (35%)
Outcomes
Death (n) 390 (44%) 245 (47%) 145 (41%)
MACE (n) 424 (48%) 262 (50%) 162 (45%)
Stroke or systemic embolism (n) 79 (9%) 42 (8%) 37 (10%)
Major bleeding (n) 43 (5%) 28 (5%) 15 (4%)
Age at the time of monocyte assessment, other clinical characteristics at the time of recruitment;
p<0.05 vs. patients not receiving OAC; ACE, angiotensin converting enzyme; BP, blood pressure; CCA, calcium channel antagonist; MACE, major adverse
cardiovascular events; OAC, oral anticoagulation
https://doi.org/10.1371/journal.pone.0200373.t001
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Statistical analysis
Descriptive statistics are presented as medians (interquartile range) for continuous variables
or numbers (percentage to the total population) for categorical variables. Predictive value of
monocyte counts for the study outcomes were assessed using univariate and multivariable Cox
regression models with monocyte levels dichotomized as above or below the 4th quartile of
their baseline levels (i.e., 580 per μL). Separate analyses were done for predictive value of per-
sistent (i.e. both the baseline and follow up) monocyte counts580 per μL. Multivariable anal-
yses included adjustments for CHA2DS2-VASc score (congestive heart failure, hypertension
[BP consistently>140/90], age75, diabetes mellitus, prior stroke or TIA or thromboembo-
lism) values for death, MACE and SSE, and an adjustment for HASBLED score (uncontrolled
hypertension [SBP>160mmHg], abnormal renal function [dialysis, transplant, creatini-
ne>2.26mg/dl or >200μmol/L, abnormal liver function [cirrhosis or bilirubin>2x normal or
AST/ALP/AP >3x normal], prior history of stroke, prior major bleeding or predisposition to
bleeding, liable INR [time in therapeutic range<60%], age>65 years, prior alcohol or drug
usage [8 drinks/week], medication usage predisposing to bleeding) values for major bleeding
events. To establish interactions between the monocyte related outcomes and use of oral antic-
oagulation, non-White ethnicity, advanced age (i.e. 75 years or older) and presence of long
standing persistent or permanent form of AF, we ran additional separate regression models
for each of the parameters and its interactions with the monocyte status added to the multivar-
iable models above. P-values of<0.05 were considered as statistically significant. STATA 13
(STATA Inc., USA) software was used for statistical analyses.
Results
We included 881 patients with a median follow up of 7.2 (4.8–10) years. The index monocyte
assessment was done 0.7 (0.1–3.0) years after the initial diagnosis of AF. Patient demographic
and clinical characteristics are presented in Table 1. At the time of the recruitment 525 (59%)
patients received OAC. Follow up monocyte data were available for 670 patients with 23
(17–33) months duration from the first sample. Persistent monocyte count580 per μL was
recorded in 84 (13%) patients.
All-cause death
Three hundred and ninety (44%) patients died during follow up (Table 1). The 4th monocyte
quartile (i.e.,580 per μL, vs. other quartiles) was associated with increased risk of death on
univariate analysis (hazard ratio [HR] 1.65, 95% confidence interval [CI] 1.32–2.06, p<0.001)
and after adjustment for CHA2DS2-VASc score (HR 1.64, 95% CI 1.31–2.05, p<0.001) (Fig 1).
Persistent monocyte levels580 per μL were associated with further increase of risk of death
(HR 1.67, 95% CI 1.21–2.32, p = 0.002 for univariate analysis and HR 1.52, 95% CI 1.10–2.11,
p = 0.011 after adjustment for CHA2DS2-VASc score).
Major adverse cardiovascular events
MACE occurred in 424 (48%) patients (Table 1). The highest monocyte quartile was associated
with an increased risk of MACE on univariate analysis (HR 1.60, 95% CI 1.29–1.98, p<0.001)
and after adjustment for CHA2DS2-VASc score (HR 1.58, 95% CI 1.28–1.96, p<0.001) (Fig 2).
Persistent monocyte levels580 per μL were associated with further increase of risk of death
(HR 1.68, 95% CI 1.24–2.29, p = 0.001 for univariate analysis and HR 1.54, 95% CI 1.13–2.09,
p = 0.006 after adjustment for CHA2DS2-VASc score).
Monocytes in atrial fibrillation
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Fig 1. Predictive value of monocytes for all-cause death. A. Univariate analysis of baseline monocyte levels; Analysis
of baseline monocytes adjusted for CHA2DS2-VASc score; B. Univariate analysis of follow up monocyte data; Analysis
of follow up monocytes data adjusted for CHA2DS2-VASc score.
https://doi.org/10.1371/journal.pone.0200373.g001
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Fig 2. Predictive value of monocytes for major adverse cardiovascular events. A. Univariate analysis of baseline
monocyte levels; Analysis of baseline monocytes adjusted for CHA2DS2-VASc score; B. Univariate analysis of follow
up monocyte data; Analysis of follow up monocytes data adjusted for CHA2DS2-VASc score.
https://doi.org/10.1371/journal.pone.0200373.g002
Monocytes in atrial fibrillation
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Stroke and systemic embolism
SSE occurred in 79 (9%) patients (Table 1). Monocyte counts were not predictive of SSE (for
baseline values: univariate analysis HR 0.88, 95% CI 0.51–1.53, p = 0.66, multivariate analysis
HR 0.85, 95% CI 0.49–1.48, p = 0.57; for persistent monocyte levels580 per μL: univariate
analysis HR 1.10, 95% CI 0.55–2.23, p = 0.78, multivariate analysis HR 1.03, 95% CI 0.51–2.08,
p>0.93) (Fig 3).
Major bleeding (including hemorrhagic stroke)
Major bleeding events occurred in 43 (5%) patients (Table 1). The highest baseline monocyte
quartile showed a non-significant trend towards the higher risk of major bleeding (HR 1.75,
95% CI 0.92–3.31, p = 0.09 for univariate and HR 1.75, 95% CI 0.93–3.32, p = 0.09 for multi-
variate analysis) (Fig 4). Persistent monocyte levels580 per μL were associated with a signifi-
cant increase in major bleeding events (HR 2.71, 95% CI 1.33–5.55, p = 0.006 for univariate
analysis, and HR 2.77, 95% CI 1.36–5.67, p = 0.005 after adjustment for HAS-BLED score).
Interactions of monocyte status with age, ethnicity and AF characteristics
On additional regression models, there were no significant interactions between the monocyte
status and use of oral anticoagulants, non-White ethnicity, advanced age and presence of long
standing persistent or permanent AF for all tested outcomes (Table 2).
Translational perspectives
The precise factors driving risk of death and MACE in AF patients with higher (but mostly still
within normal limit) monocyte counts are unclear. The likely mechanisms include the inflam-
matory and profibrotic properties of monocytes. Admittedly the mechanistic links between
monocytes and unfavorable outcomes could not be established in this analysis and monocytes
could be bystanders of ongoing pathological processes rather than direct cause of the outcome.
It is likely contributed by the fact that monocytes are a major source of inflammatory cytokines
and reactive oxygen species in the circulation.[8]
With regards to bleeding, fibrinolysis is tightly controlled by a series of cofactors, inhibitors,
and receptors.[9] Plasmin is the primary fibrinolytic enzyme, and is activated from plasmino-
gen by either of two primary serine proteases, tissue-type plasminogen activator and uroki-
nase-type plasminogen activator. Urokinase-type plasminogen activator is primarily produced
by monocytes and macrophages.[10, 11] Excessive elevation in monocyte counts or their
abnormal functional state may shift the tightly controlled local hemostasis state towards the
bleeding state. Monocyte capacity to produce matrix metalloproteases may further amplify the
process and thus overcome procoagulant monocyte properties.[12–14]
Physicians in clinical practice should be aware that higher monocyte counts signal high risk
of major bleeding in the AF population. This can aid in the decision-making process when
considering oral anticoagulation and measures to reduce bleeding risk. Future areas of
research into this field should aim to delineate possible roles of monocyte subsets in bleeding
risk and possible therapeutic measures to attenuate this bleeding risk.
Conclusion
High monocyte counts independently predict the occurrence of MACE, major bleeding
and mortality, but not SSE. This study demonstrates for the first time a strong association
between monocyte counts and the subsequent adverse outcomes of all cause death, MACE
and major bleeding in patients with AF. The similar rates of stroke/SSE in patients on or
Monocytes in atrial fibrillation
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without oral anticoagulation may be reflective of the younger average age of the population
not receiving the treatment. Furthermore, the lower CHA2DS2-VASc score in this group
reflects a lower overall baseline stroke risk. The powerful associations were present despite
adjustment for well-established scores for prognostication of thromboembolic and bleeding
Fig 3. Predictive value of monocytes for stroke and systemic embolism. A. Univariate analysis of baseline monocyte
levels; Analysis of baseline monocytes adjusted for CHA2DS2-VASc score; B. Univariate analysis of follow up
monocyte data; Analysis of follow up monocytes data adjusted for CHA2DS2-VASc score.
https://doi.org/10.1371/journal.pone.0200373.g003
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complications in AF. Indeed, the top quartile of monocyte counts were associated with a
64% rise in all-cause death and 58% increase in risk of MACE even after adjustment for the
CHA2DS2-VASc score, which accounts for major prognosticators of unfavorable cardiovas-
cular outcomes and age. Specifically, persistent monocyte levels at 580 per μL or above were
Fig 4. Predictive value of monocytes for major bleeding. A. Univariate analysis of baseline monocyte levels; Analysis
of baseline monocytes adjusted for CHA2DS2-VASc score; B. Univariate analysis of follow up monocyte data; Analysis
of follow up monocytes data adjusted for CHA2DS2-VASc score.
https://doi.org/10.1371/journal.pone.0200373.g004
Monocytes in atrial fibrillation
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associated with over 50% increase in risk of death or MACE irrespectively of the baseline
monocyte status.
The study also demonstrates for the first time that persistently high monocyte levels (i.e.,
580 per μL) are associated with almost 3-fold increase in major bleeding events. These data
support clinical relevance of previous, mostly experimental data demonstrating pro-fibrino-
lytic activity of monocytes.[12] Of note, risk of stroke was not related to monocyte counts,
despite the increased rates of other cardiovascular events. This may reflect the multidirectional
effects of monocytes, including excessive inflammation, driving risk of myocardial infarction
and death, and exaggerated fibrinolysis and connective tissue degradation predisposing to
bleeding. Accumulating data point toward the potential implication monocyte in bleeding
complications. This can be largely mediated by their three functions: production of matrix
metalloproteases, that can break the barrier between the vascular lumen and the surrounding
space, (ii) clot resolution via phagocytosis and (iii) providing surface for fibrinolysis. Further
research is needed to get further insights into these processes.[12]
Understanding the pathophysiological mechanisms involved would help understand the
relationships between monocytes, and adverse thrombotic and bleeding outcomes in AF
patients.
Limitations
The study has several limitations. Although confounding factors were considered with regards
to AF-related risk stratification, possible effects of various co-morbidities (overt or subclinical)
affecting monocyte counts have not been analysed. This is an observational analysis, and
mechanistic insights into molecular mechanisms of the findings and monocyte functional
characteristics have not been studied.[15] As the study included patients with monocytes
Table 2. Additional predictors of outcome and their interactions between monocytes.
Baseline Follow up
HR (95% CI) p for variable p for interaction HR (95% CI) p for variable p for interaction
Death
OAC use 0.77 (0.60–0.99) 0.040 0.93 0.62 (0.48–0.81) <0.001 0.50
Non-White 1.54 (1.12–2.13) 0.009 0.26 1.32 (0.96–1.83) 0.09 0.46
Age75 years 2.20 (1.65–2.91) <0.001 0.89 2.63 (1.93–3.60) <0.001 0.56
Long standing persistent or permanent AF 1.40 (1.06–1.83) 0.016 0.15 1.56 (1.15–2.10) 0.004 0.92
Major adverse cardiovascular events
OAC use 0.78 (0.62–0.99) 0.044 0.82 0.65 (0.50–0.83) 0.001 0.68
Non-White 1.40 (1.03–1.89) 0.030 0.12 1.20 (0.89–1.63) 0.24 0.09
Age75 years 1.78 (1.36–2.32) <0.001 0.97 2.05 (1.54–2.74) 0.000 0.28
Long standing persistent or permanent AF 1.33 (1.03–1.72) 0.030 0.17 1.47 (1.11–1.94) 0.008 0.91
Stroke or systemic embolism
OAC use 0.88 (0.52–1.48) 0.63 0.29 0.79 (0.47–1.32) 0.36 0.33
Non-White 0.80 (0.45–1.42) 0.45 0.80 0.85 (0.48–1.52) 0.58 0.39
Age75 years 0.59 (0.34–1.02) 0.06 0.66 0.63 (0.36–1.09) 0.10 0.98
Long standing persistent or permanent AF 1.07 (0.62–1.86) 0.81 0.19 1.01 (0.58–1.77) 0.97 0.07
Major bleeding
OAC use 1.11 (0.50–2.46) 0.81 0.81 1.51 (0.66–3.43) 0.33 0.17
Non-White 0.63 (0.28–1.42) 0.26 0.26 0.77 (0.34–1.71) 0.52 0.81
Age75 years 2.07 (0.92–4.67) 0.08 0.55 2.38 (1.04–5.45) 0.04 0.27
Long standing persistent or permanent AF 1.52 (0.67–3.44) 0.32 0.49 1.77 (0.76–4.11) 0.19 0.91
https://doi.org/10.1371/journal.pone.0200373.t002
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measured as part of routine clinical management, this could lead to some selection bias due to
not inclusion of patients with no full blood count tested at all during the routine assessment.
The medications used by the participants are likely undergone modifications during the years
of followed and all changes may not have been captured by this study.
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